摘要
目的分析中性粒细胞/淋巴细胞比值(NLR)及Glasgow评分(GPS)与肺癌预后的关系。方法选取安阳市肿瘤医院2014年1月-2016年1月收治的63例肺癌癌患者,结合相关临床资料分析NLR及GPS与肺癌病理特征的相关性,统计患者生存期,采用多因素分析法研究NLR及GPS与肺癌患者预后的关系。结果相关因素分析结果提示,TNM分期与NLR相关(P<0.05),患者年龄、性别、组织学、远处转移与NLR无关(P>0.05);TNM分期、组织学与GPS相关(P<0.05),年龄、性别、远处转移与GPS无关(P>0.05);高NLR患者的生存期明显短于低NLR患者(P<0.05),GPS与肺癌患者生存期呈负相关(P<0.05);多因素分析结果表明,NLR(OR=2.326,P=0.011)、GPS(OR=1.853,P=0.038)、TNM分期(OR=2.246,P=0.012)是影响肺癌预后的独立危险因素。结论TNM分期、NLR和GPS均与肺癌患者预后关联密切,肺癌患者TNM分期、GPS、NLR越高生存期越短,预后越差。
Objective To analyze the relationship between neutrophil/lymphocyte ratio(NLR)and GPS and the prognosis of lung cancer.Methods 63 patients with lung cancer admitted to Tumor Hospital of Anyang from January 2014 to January 2016 were selected.The correlation between NLR and GPS and the pathological characteristics of lung cancer was analyzed based on relevant clinical data,and the patients'survival period was counted.The relationship between NLR and GPS and the prognosis of lung cancer patients was studied by multi-factor analysis method.Results The related factor analysis suggest that TNM staging was correlated with NLR(P<0.05),while age,gender,histology and distant metastasis were not correlated with NLR(P>0.05).TNM staging and histology were correlated with GPS(P<0.05),while age,gender and distant metastasis were not correlated with GPS(P>0.05).The survival time of patients with high NLR was significantly shorter than that of patients with low NLR(P<0.05),and GPS was negatively correlated with the survival time of patients with lung cancer(P<0.05).Multivariate analysis showed that NLR(OR=2.326,P=0.011),GPS(OR=1.853,P=0.038)and TNM stage(OR=2.246,P=0.012)were independent risk factors affecting the prognosis of lung cancer.Conclusion TNM stage,NLR and GPS are closely related to the prognosis of lung cancer patients.The higher TNM stage,GPS and NLR,the shorter the survival period and the worse the prognosis of lung cancer patients.
作者
陈涛
许海生
杨晓虹
CHEN Tao;XU Haisheng;YANG Xiaohong(Tumor Hospital of Anyang,the Fourth Affiliated Hospital of Henan University of Science and Technology,Anyang Henan 455000,China)
出处
《临床研究》
2019年第12期139-141,共3页
Clinical Research